ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners

ARS Pharmaceuticals (NASDAQ:SPRY) had its price target upped by Leerink Partners from $26.00 to $27.00 in a research report report published on Monday,Benzinga reports. They currently have an outperform rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $24.50.

ARS Pharmaceuticals Price Performance

SPRY opened at $11.26 on Monday. The business’s 50-day moving average is $12.95 and its two-hundred day moving average is $12.78. ARS Pharmaceuticals has a 1 year low of $5.75 and a 1 year high of $18.51. The firm has a market capitalization of $1.09 billion, a PE ratio of -22.08 and a beta of 0.96.

Insider Transactions at ARS Pharmaceuticals

In related news, COO Brian Dorsey sold 25,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $12.30, for a total transaction of $307,500.00. Following the completion of the sale, the chief operating officer now owns 6,024 shares of the company’s stock, valued at $74,095.20. The trade was a 80.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $18.04, for a total value of $9,533,346.24. Following the sale, the insider now directly owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. This trade represents a 9.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,108,058 shares of company stock worth $17,053,686. Insiders own 40.10% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. J.W. Cole Advisors Inc. lifted its holdings in ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after acquiring an additional 1,500 shares during the period. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals in the third quarter valued at approximately $30,000. Creative Planning lifted its holdings in ARS Pharmaceuticals by 7.0% in the third quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after acquiring an additional 2,307 shares during the period. HighTower Advisors LLC lifted its holdings in ARS Pharmaceuticals by 18.2% in the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in ARS Pharmaceuticals by 9.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock valued at $836,000 after acquiring an additional 4,810 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.